Comparative Pharmacology
Head-to-head clinical analysis: CHIBROXIN versus MOXIFLOXACIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHIBROXIN versus MOXIFLOXACIN HYDROCHLORIDE.
CHIBROXIN vs MOXIFLOXACIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chibroxin (norfloxacin) is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication, transcription, repair, and recombination.
1-2 drops of 0.3% ophthalmic solution into affected eye(s) every 2 hours while awake for the first 2 days, then every 4 hours for 5-7 days.
400 mg orally or intravenously once daily for most indications; duration varies by indication.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours in adults with normal renal function. Prolonged to 12-24 hours in moderate renal impairment (CrCl 30-50 mL/min) and >24 hours in severe impairment (CrCl <30 mL/min).
Terminal elimination half-life is approximately 12-14 hours in healthy adults, allowing once-daily dosing. This is extended in severe renal impairment (creatinine clearance <30 mL/min) and in the elderly.
Renal: 98% as unchanged drug; hepatic: 2% as minor metabolites. Biliary/fecal excretion negligible.
Approximately 20% of a dose is excreted unchanged in urine, with about 25% recovered as a glucuronide conjugate (M1) and a sulfate conjugate (M2). Biliary/fecal excretion accounts for about 55% of the dose, with a portion undergoing enterohepatic recirculation.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic